It has reported that the addition of pembrolizumab to docetaxel and cisplatin (TP) ex vivo leads to a greater suppression of monocyte chemoattractant protein 1 (MCP-1), interferon-γ (IFN-γ), and interleukin-6 production in head and neck squamous cell carcinoma than what is observed with TP alone. This evidence concerns the gene CCL2 and head and neck squamous cell carcinoma.